CAZZANIGA MARINA ELENA

Malighetti, F., Villa, M., Villa, A., Pelucchi, S., Aroldi, A., Cortinovis, D., et al. (2025). Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 26(5) [10.3390/ijms26051943]. Detail

Cazzaniga, M., Pronzato, P., Amoroso, D., Arpino, G., Atzori, F., Beano, A., et al. (2025). Survival Outcomes of Luminal Metastatic Breast Cancer Patients According to Changes in Molecular Subtype at Re-Biopsy: Insights from the GIM-13—AMBRA Study. CANCERS, 17(10) [10.3390/cancers17101715]. Detail

Cazzaniga, M., Huober, J., Tamma, A., Emde, A., Thoele, K., O'Shaughnessy, J. (2025). Oral Anticancer Therapies: Addressing Nonadherence in Patients With Breast Cancer. CLINICAL BREAST CANCER, 25(4), 307-324 [10.1016/j.clbc.2024.12.011]. Detail

Ardakani, K., Pepe, F., Capici, S., Clementi, T., Cazzaniga, M. (2025). Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC). CURRENT ONCOLOGY, 32(7) [10.3390/curroncol32070387]. Detail

Turner, N., Saura, C., Aftimos, P., Van Den Tweel, E., Oesterholt, M., Koper, N., et al. (2025). Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP). JOURNAL OF CLINICAL ONCOLOGY, 43(5), 513-523 [10.1200/JCO.24.00529]. Detail